Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response

Circulation

Volumn 107, Issue 25, 2003, Pages 3165-3169

  Silvestri, Antonello ^a   Gebara, Otavio ^b   Vitale, Cristiana ^a   Wajngarten, Mauricio ^b   Leonardo, Filippo ^a   Ramires, Josè A F ^b   Fini, Massimo ^a   Mercuro, Giuseppe ^b   Rosano, Giuseppe M C ^a  

^a Cardiovascular Research Unit   (Italy)

^b San Raffaele Roma ^*

Author keywords

Cardiovascular diseases; Inflammation; Interleukins

Indexed keywords

C REACTIVE PROTEIN; CONJUGATED ESTROGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MEDROXYPROGESTERONE ACETATE; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; LIVER METABOLISM; MAJOR CLINICAL STUDY; PLASMA; POSTMENOPAUSE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COMPLEMENT C3; COMPLEMENT C4; E-SELECTIN; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LIVER; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; THROMBOMODULIN; TIME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0038417544     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000074208.02226.5E     Document Type: Article

References (32)

1. Sbarouni E, Kroupis C, Kyriakides S, et al. Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease. Eur Heart J. 2000;21:975-980.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for 1990s. Nature. 1993;362:801-809.
3. Nakagomi A, Freedman SB, Geczy CL, et al. Interferon and Lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein. Circulation. 2000;101:1785-1791.
4. Garcia-Moll X, Zouridakis E, Cole D, et al. C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. Eur Heart J. 2000;21:1598-1606.
5. Marchien van Baal W, Kenemans P, Emeis JJ, et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril. 1999;71:663-670.
6. Wilcox JG, Hatch IE, Gentzschein E, et al. Endothelin levels decrease after oral and non-oral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil Steril. 1997;67:273-277.
7. Wolbink GJ, Brouwer MC, Buysmann S, et al. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol. 1996;157:473-479.
8. Torzewski J, Bowyer DE, Waltemberger J, et al. Processes in atherogenesis: complement activation. Atherosclerosis. 1997;132:131-138.
9. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000;85:214-218.
10. Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36:1286-1294.
11. Maseri A. C-Reactive protein in cardiovascular risk prediction: zooming in and zooming out. Ital Heart J. 2001;2:155-156.
12. Mancia G, Mariani M, Paoletti R. A synthesis of the guidelines of the ESC/EAS/ESH on the prevention of coronary disease and of the guidelines of the Task Force for the Prevention of Coronary Heart Disease. Eur Soc Cardiol Ital Heart J. 2000;1(5 suppl):690-691.
13. Decensi A, Omodei U, Roberson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation. 2002;106:1224-1228.
14. De Maat MP, Pietersma A, Kofflard M, et al. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis. 1996;121:185-191.
15. Cioffi M, Esposito K, Vietri MT, et al. Cytokine pattern in postmenopause. Maturitas. 2002;41:187-192.
16. Girasole G, Giuliani N, Modena AB, et al. Oestrogens prevent the increase of human serum soluble interleukin-6 receptor induced by ovariectomy in vivo and decrease its release in human osteoblastic cells in vitro. Clin Endocrinol. 1999;51:801-807.
17. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
18. Douketis JD, Gordon M, Johnston M, et al. The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of the literature. Thromb Res. 2000;99:25-34.
19. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. JAMA. 2002;288:980-987.
20. Barret-Connor E, Grady D. Hormone replacement therapy, heart disease and other consideration. Annu Rev Public Health. 1998;19:55-72.
21. Hulley S, Grady D, Bush T, et al for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
22. Rossouw JE, Anderson GL, Prentice RL, et al for the Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;228:321-333.
23. Grady D, Herrington D, Bittner V, et al for HERS II. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 2002;288:49-57.
24. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999;100:717-722.
25. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713-716.
26. Toss H, Lindahl B, Siegbahn A, et al. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation. 1997;96:4204-4210.
27. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently health women. Circulation. 1998;98:731-733.
28. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287:847-857.
29. Wenger NK, Barrett-Connor E, Collins P, et al. Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol. 2002;90:1204-1210.
30. Koh KK, Ahn JY, Jin DK, et al. Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women. Arterioscler Thromb Vasc Biol. 2002;22:1459-1464.
31. Koh KK, Schenke WH, Waclawiw MA, et al. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation. 2002;105:1531-1153.
32. Koh KK, Kang MH, Jin DK, et al. Vascular effects of estrogen in type II diabetic postmenopausal women. J Am Coll Cardiol. 2001;38:1409-1415.